Predict your next investment

Angel Investor (Individual)

See what CB Insights has to offer

Investments

9

Portfolio Exits

1

About Harald Mix

Harald Mix Headquarter Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Harald Mix News

Anocca Raises $47M in Series B Financing

Jul 22, 2021

Anocca AB , a Sodertalje, Sweden-based developer of therapeutics for cancer leveraging the potential of T-cell immunotherapy, closed a USD 47m (SEK 400m) Series B financing. Backers included Swedbank Robur Ny Teknik, Ramsbury Invest and family offices including those of Harald Mix and Robert Andreen and existing investors including Mellby Gård, Nidoco and co-founder Mikael Blomqvist via Michano. The company intends to use the funds to further advance its industrialised cellular biology platform and progress its pipeline of TCR-T cellular therapies into Phase I/IIa clinical trials. Led by CEO and co-founder Reagan Jarvis, Anocca leverages a cellular biology platform that replicates human T-cell biology in the laboratory, to generate targeted T-cell therapies with broad applicability in oncology, infectious diseases and autoimmune disorders. The platform is comprised of a number of proprietary cell biology and molecular genetics technologies and enables the high-precision analysis needed to develop highly targeted therapeutics that leverage T-cell immunity. The platform is underpinned by proprietary, fully integrated, information management and bioinformatic software tools developed in-house. Anocca has delivered a broad pipeline of T-cell receptor (TCR) assets to generate novel TCR-modified T-cell therapies (TCR-T) against multiple antigen classes, including targets that are shared amongst tumours, against specific genetic mutations that drive cancer, and against viruses that cause cancer. TCR-T cellular therapies can unlock an immense target space inaccessible to biologics and CAR-T therapies and is emerging as an important treatment modality for many forms of cancer. The company has a team of over 65 employees. FinSMEs

Harald Mix Investments

9 Investments

Harald Mix has made 9 investments. Their latest investment was in Gimi as part of their Series B on August 8, 2021.

CBI Logo

Harald Mix Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/30/2021

Series B

Gimi

$2.08M

No

1

7/22/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

10/16/2020

Series B

Subscribe to see more

$99M

Subscribe to see more

10

4/9/2020

Angel

Subscribe to see more

$99M

Subscribe to see more

10

6/25/2019

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/30/2021

7/22/2021

10/16/2020

4/9/2020

6/25/2019

Round

Series B

Series B

Series B

Angel

Series B - II

Company

Gimi

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$2.08M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

10

10

10

10

Harald Mix Portfolio Exits

1 Portfolio Exit

Harald Mix has 1 portfolio exit. Their latest portfolio exit was Invajo on May 14, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/14/2020

IPO

1

Date

5/14/2020

Exit

IPO

Companies

Valuation

Acquirer

Sources

1

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.